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Abstract
Background: Pneumococcal disease is a leading cause of morbidity and mortality worldwide. The aim of this study was to
investigate the association between specific pneumococcal serotypes and mortality from invasive pneumococcal disease
(IPD).
Methods and Findings: In a nationwide population-based cohort study of IPD in Denmark during 1977–2007, 30-d
mortality associated with pneumococcal serotypes was examined by multivariate logistic regression analysis after
controlling for potential confounders. A total of 18,858 IPD patients were included. Overall 30-d mortality was 18%, and 3%
in children younger than age 5 y. Age, male sex, meningitis, high comorbidity level, alcoholism, and early decade of
diagnosis were significantly associated with mortality. Among individuals aged 5 y and older, serotypes 31, 11A, 35F, 17F, 3,
16F, 19F, 15B, and 10A were associated with highly increased mortality as compared with serotype 1 (all: adjusted odds ratio
$3, p,0.001). In children younger than 5 y, associations between serotypes and mortality were different than in adults but
statistical precision was limited because of low overall childhood-related mortality.
Conclusions: Specific pneumococcal serotypes strongly and independently affect IPD associated mortality.
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Invasive pneumococcal disease (IPD) remains a major cause of
morbidity and mortality worldwide despite the availability of
antibiotic therapy and vaccines. Developing countries bear the
major burden of IPD along with significantly higher rates of death
and disability [1–3]. The introduction of a 7-valent pneumococcal
conjugate vaccine (PCV7) for infants has significantly reduced
rates of bacteremic and nonbacteremic pneumococcal disease in
the United States and other industrialized countries, yet the
emergence of nonvaccine pneumococcal serotypes may threaten
the continued efficacy of conjugate vaccines [1,4–6]. Unfortu-
nately, since the prevalence of pneumococcal serotypes varies
among geographical regions, the formulation of PCV7 is not
optimal against the most prevalent serotypes found in the
developing world [7]. In addition, some controversy surrounds
the use of the available 23-valent polysaccharide vaccine (PPV23),
which is recommended for patients of 2 y and older with high-risk
conditions and for the elderly, since controlled trials were
inconclusive and observational data suggested that PPV23 may
prevent bacteremic but not nonbacteremic disease [8,9].
Host and bacterial factors both contribute to IPD pathogenicity.
Ethnicity, extremes of age, existence of comorbidities, alcoholism,
and immunosuppression including HIV-1 infection are well-
known risk factors associated with an increased susceptibility to
IPD and are further associated with higher mortality [10–12]. The
capsular polysaccharide is a major pneumococcal virulence factor
that triggers a specific immunological response to infection and
vaccination and constitutes an important determinant of the
potential of Streptococcus pneumoniae to cause invasive and severe
disease [13–15]. Experimental studies in animal models have
shown that pneumococcal capsular serotypes differ in their ability
to trigger inflammatory responses [16,17]. Clinical studies in the
pre- and postantibiotic era have also suggested that capsular
polysaccharides are associated with specific manifestations of
pneumococcal disease and mortality [10,13,15,18–24]. However,
only a few studies have evaluated the association of specific
capsular serotypes with mortality from IPD in recent time and
have delivered conflicting results [10,20,25,26]. Most investiga-
tions were clinic-based studies from referral centers with few
outcomes and limited confounder control, so their interpretation is
limited.
Here we report our investigation of the association between
specific invasive pneumococcal serotypes and mortality related to
IPD, after controlling for important confounders, in a large
population-based cohort study including more than 18,000
hospitalized IPD patients.
Material and Methods
Study Setting and Design
We conducted a nationwide population-based cohort study
based on the linkage of IPD laboratory surveillance data to several
Danish nationwide medical databases. Linkage between data
sources was done by using the unique ten-digit identification
number provided to all residents in Denmark [27]. The study was
approved by the Danish Data Protection Agency (2007-41-0229).
Laboratory surveillance data on IPD were obtained from the
National Neisseria and Streptococcus Reference Center (NSR),
Statens Serum Institut (SSI), from 1 January 1977 through 31
December 2007. Isolates were routinely serotyped by pneumotest
latex and Quellung reaction using type-specific pneumococcal
rabbit antisera from SSI as previously described (SSI-Diagnostica,
Copenhagen, Denmark) [28,29]. Laboratory surveillance in
Denmark is based on the voluntary submission of S. pneumoniae
isolates cultured from a normally sterile site from all local
departments of clinical microbiology to the NSR [30]. The
coverage of the laboratory surveillance system has recently been
estimated to reach more than 90% of the total Danish population
[31].
PCV7 was introduced into the Danish childhood immunization
program in October 2007 and the vaccine is currently adminis-
tered free of charge to children at the ages of 3, 5, and 12 mo [31].
Between 2001 and 2007, vaccination with PCV7 was recom-
mended only for children younger than 2 y belonging to high-risk
groups [32]. An estimate of the proportion of the uptake of PCV7,
based on the number of doses sold in Denmark (and assuming that
all vaccines were given in a three-dose series to children younger
than 2 y), ranges from 0.6 to 1.4 per 1,000 children between 2001
and 2006. The PPV23 has been recommended for patients older
than 2 y at high risk and the elderly since 1996 in Denmark;
however the uptake of PPV23 remains low. A similar estimate
based on the number of doses of PPV23 sold per year (assuming
that only persons $65 y, and older received one dose of the
vaccine), suggest that the uptake has declined from approximately
30 to 17 doses per 1,000 persons aged 65 y and older between
1998 and 2007 (estimates based on unpublished data from SSI,
Sales and Development Department, and The Danish Medicines
Agency, http://www.dkma.dk/).
The percentage of invasive pneumococcal isolates with
decreased susceptibility to b-lactam antibiotics or macrolides has
remained low in Denmark, i.e., between 2% and 5% per year
since 1991 when the first intermediate and resistant isolates were
described [33,34].
Case Definition
A case was defined as an occurrence of IPD confirmed by
positive culture for S. pneumoniae from a hospitalized patient’s
cerebrospinal fluid (CSF) or blood. When CSF isolates or both
CSF and blood isolates were received simultaneously, the case was
categorized as meningitis. Additionally, bacteremic patients who
received a WHO International Classification of Disease (ICD)-8th
or 10th code at discharge corresponding to bacterial meningitis
(ICD-8 code 320, or ICD-10 codes A39, G00-G03) were
considered to have a case of meningitis. All other cases were
categorized as bacteremia. For patients with recurrent IPD
episodes, only the first IPD episode was included in the analysis.
Only patients with IPD who where hospitalized within one week
of the date of sampling were included in the study. Patients were
excluded from the analysis due to one of the following reasons: (1)
a provisional or invalid identification number (e.g., given to
foreigners not residing in Denmark admitted to Danish hospitals),
(2) emigration within 3 mo after the IPD admission, or (3) patients
from whom samples were obtained outside the one-week criterion
of admission to a hospital, as stated above.
Data on Comorbidity and Outcome
All residents in Denmark had free access to primary care and
hospitals provided by the National Health Services during the
study period. The Danish National Hospital Register contains
data on all hospitalizations since 1977 and on all outpatient visits
since 1995 [35].
Comorbidity was assessed by computing the Charlson index
score for each patient by using ICD codes from all available
discharge diagnoses, as previously described [36,37]. Briefly, the
Charlson index is used to score patients’ comorbid conditions in
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seriousness of comorbid diseases. We defined three levels of
comorbidity prior to the IPD admission: low (score of 0),
intermediate (1–2), and high ($3).
Patients’ discharge diagnoses were coded by physicians based on
the ICD 8th revision (ICD-8, from 1977 through 1993) and the
10th revision (ICD-10) from January 1994. Since alcoholism-
related conditions are not included in the Charlson index, we
ascertained them separately by considering the following diagnosis
codes: for ICD-8 classification: 291, 303, 979, 980, 577.10, 571.09,
571.10; and for ICD-10 classification: F10, G31.2, G62.1, G72.1,
I42.6, K29.2, K86.0, K70, R78.0, T51, Z72.1.
The study’s endpoint was death from any cause within 30 d
following the IPD-related admission. Information on dates of
death was obtained from the Danish Civil Registration System
[27]. Data were retrieved 6 mo after the last patient was included
in the study (1 July 2008).
Statistical Analysis
Values for continuous variables are expressed as medians and
interquartile ranges (IQRs). p-Values for the differences between
groups were estimated by a Wilcoxon two-sample test. Associa-
tions between pneumococcal serotypes and 30-d mortality, after
controlling for other confounders, were tested in multivariate
analyses using a logistic regression model and expressed by odds
ratio (OR) estimates with 95% confidence intervals (95% CIs).
Crude and adjusted OR estimates for pneumococcal serotypes
with a frequency of $50 cases were calculated. Cases of IPD
caused by serotype 1 were chosen as the reference group, because
serotype 1 represents the single most frequent serotype in our
study population. The following variables were included in the
logistic regression model: age, sex, IPD focus (bacteremia versus
meningitis), comorbidity estimated by Charlson index, alcoholism-
related conditions, and calendar period (1977–1986, 1987–1996,
and 1997–2007). Depending on the explanatory model, IPD focus
might or might not be considered an intermediate in the causal
pathway between serotype and mortality, and analyses were
therefore done both with and without inclusion of the focus of
infection in the logistic regression model. Associations were tested
separately among IPD patients younger than 5 y and those aged 5
y and older, and in the latter group further stratified by level of
comorbidity (low, intermediate, high) and IPD focus (meningitis or
bacteremia). p-Values,0.05 were considered significant. Data
were analyzed using SAS Software, version 9.1 (SAS Institute,
Cary, North Carolina, United States).
Serotypes were furthermore ranked according to their relative
prevalence in the study population, by the crude number of deaths
associated with each serotype, and by their population-attributable
risk (PAR) of death among patients aged 5 y and older. The
cumulative numbers of deaths associated with serotypes ranked in
this manner were then compared with deaths associated with
serotypes included in the existing PCV formulations containing up
to 13 serotypes, using Chi-square tests with Yates correction, and
two-tailed p-values were obtained. We calculated the PAR of death
for each serotype using their prevalence proportion (PP) and
adjusted mortality OR (as a measure of relative risk, RR) versus
serotype 1 in the following equation [38]: PAR=PP6(RR21)/
(PP6[RR21]+1), with 95% CIs computed as previously described
[38,39].The serotypes included in current and investigational
pneumococcal protein conjugate vaccine formulations at the
moment are: serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in the
PCV7 (Wyeth); serotypes 1, 5, and 7F are additionally included in
the ten-valent pneumococcal nontypeable Haemophilus influenzae
protein D-conjugate vaccine (PHiD-CV; GlaxoSmithKline); and
serotypes 3, 6A, and 19A in the 13-valent pneumococcal conjugate
vaccine (PCV13; Wyeth).
Results
Study Population and Patient Characteristics
The Danish population numbered 5,080,000 inhabitants in
1977 and 5,447,084 in 2007. More than 90% of the population
has a Danish ethnic background (http://www.statistikbanken.dk/).
In total, 20,767 consecutive IPD cases were registered between 1
January 1977 and 31 December 2007. Of these, ,10% (n=1,970)
were excluded from the present analysis for one of the following
reasons: (1) patients who presented another focus than bacteremia
or meningitis (n=172), (2) patients who had no hospital admission
recorded within 7 d before and after the sampling date (n=1,782),
and (3) emigration (n=16). The serotype distribution and overall
mortality among excluded patients was similar to that encountered
in the study population (unpublished data).
In total, 18,858 patients with pneumococcal meningitis or
bacteremia were included in the present study (Table 1).
Approximately 90% of patients (n=17,277) were 5 y and older,
half were female (n=9,424), and 15% had meningitis (n=2,762).
Among adolescents and adults ($15 y), bacteremia patients were
older than meningitis patients (median [IQR]: 68 y [54–78 y]
versus 62 y [49–72 y]; p,0.001). Similarly, among children
younger than 5 y, bacteremia patients were older than meningitis
patients (1.2 y [0.9–1.8 y] versus 0.8 y [0.5–1.3 y], p,0.001) The
overall 30-d mortality following the IPD-related admission was
18%, but 3% in children younger than 5 y, 14% in patients
between 5 y and 64 y, and 24% among patients aged 65 y and
older.
Serotype Distribution and Pneumococcal Serotype Crude
Mortality Proportions
Capsular serotypes were available for all isolates obtained from
IPD cases included in the study. We identified 77 different
serotypes among invasive isolates including nonserotypeable
isolates using pooled sera. No cases of serotypes 9L, 10C, 11F,
11C, 11D, 19C, 25A, 32A, 32F, 33D, 40, 47F, and 47A were
identified.
Age-specific serotype distributions have previously been de-
scribed in parts of the study period [31,34]. Briefly, serotype 1 was
the most common serotype and accounted for 15% of all IPD
cases in the study population, followed by serotypes 14, 4, 7F, 9V,
3, 8, 12F, 23F, and 6B. Ten serotypes accounted for approxi-
mately 80% of IPD cases in children younger than 5 y: 14, 6B,
18C, 7F, 19F, 1, 6A, 23F, 4, and 9V. Serotypes 6B, 14, 7F, 18C,
19F, 6A, and 23F accounted for 70% of meningitis cases in this
age group. Among patients aged 5 y and older, the most frequent
serotypes were 1, 4, 14, 7F, 3, 9V, 12F, 8, and 23F, accounting for
67% of all cases. Serotype 3 was frequent across all age groups
except children younger than 5 y, in whom it constituted less than
1% of the infections. Serotype 6B was less frequent among the
elderly, while serotypes 4, 14, and 7F were found across all groups
of patients.
Among meningitis cases, serotypes 7F, 14, 12F, 6B, 3, and 4
were each encountered in 6%–7% of patients. The serotype
distribution in patients with different levels of comorbidity was
similar across the strata, with serotypes 1, 3, 4, 8, 6B, 7F, 9V, 12F,
14, 19F, and 23F, causing more than 60% of IPD in patients with
any level of comorbidity. Serotypes’ specific prevalence and crude
mortality proportions stratified by age, focus of infection, and level
of comorbidity (only for patients aged 5 y and older) are shown in
Figures 1–7.
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Figures 1–7 show serotype-specific 30-d mortality propor-
tions and crude and adjusted 30-d mortality OR estimates as
compared with serotype 1. Results are shown for IPD patients
stratified by age group: Figure 1 shows results for children
younger than 5 y; Figure 2 shows results for patients 5 y or
older. For patients aged 5 y and older the stratification was
done also by IPD focus (Figures 3 and 4) and level of
comorbidity (Figures 5–7). Only serotypes identified in $50
cases in every stratified model were included separately in the
analysis. Serotypes identified in ,50 cases were categorized as
‘‘other.’’
After controlling for prognostic covariates, 27 serotypes were
statistically significantly associated with increased 30-d mortality in
the cohort of patients aged 5 y and older (Figure 2). Serotypes 31,
11A, 35F, 17F, 3, 16F, 19F, 15 B, and 10A were associated with
adjusted OR estimates $3 as compared with serotype 1 in this age
group. The associations were mainly driven by bacteremia cases
(Figures 3 and 4). When not adjusting for IPD focus in the logistic
regression model, the 30-d mortality OR estimates for most
serotypes were even higher than for serotype 1, since focus
adjustment controlled for the disposition of serotype 1 to cause
bacteremia rather than meningitis, which has a worse prognosis
(Tables S1 and S2).
Table 1. Characteristics of patients hospitalized with IPD and 30-d mortality proportions by age group, Denmark, 1977–2007
(n=18,858).
Category Patients ,5 y Patients $5 y Overall
Total Mortality (%) Total Mortality (%) Total Mortality (%)
Sex
Female 641 18 (3) 8,783 1,631 (18) 9,424 1,649 (17)
Male 940 23 (2) 8,494 1,730 (20) 9,434 1,753 (19)
Charlson index
Low (0) 1,462 38 (3) 9,059 1,321 (14) 10,521 1,359 (13)
Intermediate (1–2) 108 1 (1) 5,536 1,247 (22) 5,644 1,248 (22)
High ($3) 11 2 (18) 2,682 793 (30) 2,693 795 (30)
Alcoholism-related conditions
No 1,581 41 (3) 16,131 3,019 (19) 17,712 3,060 (17)
Yes — — 1,146 342 (30) 1,146 342 (30)
IPD focus
Bacteremia 1,067 17 (2) 15,029 2,776 (18) 16,096 2,793 (17)
Meningitis 514 24 (5) 2,248 585 (26) 2,762 609 (22)
All 1,581 41 (3) 17,277 3,361 (19) 18,858 3,402 (18)
doi:10.1371/journal.pmed.1000081.t001
Figure 1. Multivariate logistic regression analysis of serotype-specific 30-d mortality associated with IPD in children younger than 5
y( n=1,581). OR estimates adjusted for age (in years), sex, IPD focus (meningitis or bacteremia), time at diagnosis (in decades), alcoholism-related
conditions, and low, medium, or high comorbidity score estimated by the Charlson index. The reference group was patients with IPD caused by
serotype 1 in each group. ORs were calculated for serotypes with $50 IPD cases only.
doi:10.1371/journal.pmed.1000081.g001
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serotypes and mortality tended to be different from those observed
in older patients. In children younger than 5 y, the case fatality for
serotype 1 was among the highest of the serotypes evaluated, while
serotypes 14, 6A, 7F, and 4 tended to be associated with decreased
mortality compared with serotype 1. However, because of low
childhood mortality, statistical precision was limited and no
statistically significant differences in mortality between serotypes
were found (Figure 1).
Among patients aged 5 y and older with meningitis, most
serotypes were associated with higher 30-d mortality than serotype
1, similar to findings in the bacteremia group, but we did not find
statistically significant differences between serotypes (Figure 3). In
patients aged 5 y and older with high levels of comorbidity, only
serotypes 3, 11A, 19F, and 23F were found to be independently
associated with mortality (Figure 7).
The following prognostic covariates included in the regression
model together with pneumococcal serotypes were independently
associated with 30-d mortality among patients aged 5 y and older:
age per year increment (1.02 [1.02–1.03], p,0.001), male versus
female sex (1.19 [1.09–1.29], p,0.001), meningitis versus
bacteremia (1.90 [1.70–2.14], p,0.001), high Charlson index
(1.85 [1.66–2.07], p,0.001) and intermediate Charlson index
(1.35 [1.23–1.48], p,0.001) versus low Charlson index, a history
of alcoholism-related conditions versus no such history (2.40
[2.08–2.78], p,0.001), and earlier decades of diagnosis: 1977–
1986 (1.33 [1.16–1.52], p,0.001), and 1987–1996 (1.20 [1.10–
1.31], p,0.001) compared to 1997–2007 (Table S2).
In children younger than 5 y, the following covariates were
independently associated with 30-d mortality: meningitis versus
bacteremia (2.05 [1.02–4.09], p=0.04), high Charlson index
(28.12 [4.34–181.83], p,0.001) versus low Charlson index, and
Figure 2. Multivariate logistic regression analysis of serotype-specific 30-d mortality associated with IPD in patients aged 5 y or
older (n=17,277). OR estimates adjusted for age (in years), sex, IPD focus (meningitis or bacteremia), time at diagnosis (in decades), alcoholism-
related conditions, and low, medium, or high comorbidity score estimated by the Charlson index. The reference group was patients with IPD caused
by serotype 1 in each group. ORs were calculated for serotypes with $50 IPD cases only.
doi:10.1371/journal.pmed.1000081.g002
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p=0.006) compared to 1997–2007.
Comparisons of Conjugate Vaccine Formulations
Considering Prevalence and Mortality Data
To study whether alternative vaccine formulations that
address serotype-specific mortality could prevent more cases
and deaths, we used three approaches to rank serotypes: a
prevalence-based score, a crude mortality score, and a PAR of
death score, and compared them to current conjugate vaccine
formulations. Because PARs of death were calculated based on
confounder-adjusted mortality ORs, the resulting serotype
ranking and cumulative number of deaths was different than
that based on crude mortality. Due to the few deaths, low
statistical precision, and many adjusted ORs below 1 versus the
chosen reference group among children, we calculated PARs of
death only among patients 5 y and older. Results are shown for
children younger than 5 y in Table 2 and patients aged 5 y or
older in Table 3.
In children younger than 5 y, a vaccine containing either the
most prevalent serotypes in our population, the serotypes with the
highest associated crude mortality and the serotypes contained in
current vaccines formulations (PCV7, PHiD-CV, and PCV13),
would potentially prevent a comparable number of deaths.
In patients aged 5 y and older, an empirical vaccine containing
either the seven most prevalent serotypes in our population, the
seven serotypes with the highest associated crude mortality, or the
highest PARs of death would potentially prevent a higher number
of deaths compared with PCV7. However, for vaccines containing
ten or more serotypes the differences were not statistically
significant.
Discussion
Our study is, to our knowledge, the largest and most
comprehensive population-based study to date that evaluates
short-term mortality associated with invasive pneumococcal
serotypes after adjustment for possible confounders. The results
support the hypothesis that specific pneumococcal capsular
serotypes are significantly and independently associated with
short-term mortality in patients with IPD. This observation is of
particular interest in the era of conjugate vaccination, because a
limited number of serotypes are included in the vaccines and
because of the current emergence of nonvaccine serotypes.
Our results confirm that age, comorbid conditions, and clinical
presentation affect serotype distribution as well as determine
outcome from IPD [10,20,24,40] (Figures 1–7). Few other
population-based studies have investigated confounder-adjusted
serotype-specific mortality, and they produced conflicting results
and explored a relatively limited number of serotypes
[10,19,21,24,25,41,42].
In accordance with our findings, previous studies have suggested
that highly invasive serotypes, e.g., serotypes 1, 7F, and 14, are
associated with lower mortality proportions and are more likely to
be invasive in younger patients who have fewer comorbid
conditions [16,21,41]. The pathogenic basis for these observations
is unknown. Epidemiological and experimental studies have
identified serotype 3 and 11A and serotypes included in serogroup
9 as serotypes that are more likely to cause severe disease
[16,19,20,41]. Future research should be directed at identifying
virulence mechanisms that could improve our understanding of
these associations and should explore potential implications for the
clinical management of IPD patients.
Figure 3. Multivariate logistic regression analysis of serotype-specific 30-d mortality associated with IPD in meningitis patients
aged 5 y or older (n=2,248). OR estimates adjusted for age (in years), sex, time at diagnosis (in decades), alcoholism-related conditions, and low,
medium, or high comorbidity score estimated by the Charlson index. The reference group was patients with IPD caused by serotype 1 in each group.
ORs were calculated for serotypes with $50 IPD cases only.
doi:10.1371/journal.pmed.1000081.g003
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models have indicated that there are serotype-related differences in
the inflammatory response and in brain damage [16,17]. Overall,
we found fewer differences in mortality among all serotypes that
caused meningitis, indicating that host factors are more important
than serotypes as determinants of outcome from pneumococcal
meningitis. Further clinical and experimental studies are needed in
this field in order to elucidate whether differences in the early
inflammatory response of the host lead to differences in severity of
disease and short-term mortality after pneumococcal meningitis.
Furthermore, studies exploring the notion that certain serotypes are
more likely to cause meningitis than other less severe forms of
pneumococcal disease should be conducted in the future.
Since the introduction of universal conjugate vaccination in
several industrialized countries [43], the clinical epidemiology of
IPD has changed dramatically, and ‘‘replacement’’ disease caused
by nonvaccine serotypes has caused concern [5,44–46]. Our
results indicate that serotypes recently identified as potential
(re-)emerging serotypes, such as serotype 3 and 19A, are associated
with relatively high mortality in individuals aged 5 y and older
compared with serotype 1 and other serotypes included in PCV7
[4,5,20]. Other serotypes (e.g., 31, 11A, 35F, 17F, 16F, 10A, 15B,
23A, and 9N) that have not yet been identified as emerging
serotypes were alsoassociated with higher mortalitythan serotype 1.
Our results support that comorbidity plays an important role in
mortality after IPD [10,21,47]. Interestingly, a Swedish study [21]
recently indicated that comorbidity may influence the invasiveness
of specific serotypes in susceptible populations, suggesting that
serotypes with low invasive disease potential may behave as
opportunistic pathogens in patients with underlying comorbidity.
We observed that patients with high levels of comorbidity were
overrepresented among cases of serotypes 31, 11A, 35F, 17F. This
observation supports the opportunistic pathogen hypothesis [21]
and is of potential concern because serotype replacement may
have particular implications for immunocompromised individuals,
including HIV-1–infected individuals, in terms of severity of
disease and related mortality.
In this study, pneumococcal serotypes other than those in older
patients tended to cause the highest mortality estimates in children
younger than 5 y, who are the primary target for conjugate
Figure 4. Multivariate logistic regression analysis of serotype-specific 30-d mortality associated with IPD in bacteremia patients
aged 5 y or older (n=15,029). OR estimates adjusted for age (in years), sex, time at diagnosis (in decades), alcoholism-related conditions, and low,
medium, or high comorbidity score estimated by the Charlson index. The reference group was patients with IPD caused by serotype 1 in each group.
ORs were calculated for serotypes with $50 IPD cases only.
doi:10.1371/journal.pmed.1000081.g004
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serotype–mortality associations could be demonstrated for children
even in this large cohort, because of the very low overall childhood
IPD-related mortality (less than 3%). Nonetheless, significant
differences in serotype-specific mortality and severity of disease in
childrenmightbeobservedindevelopingcountries,wherechildhood
mortality ranges from 10% to 40% [1] due to, among many other
factors, poorer access to health care and a higher prevalence of
comorbid conditions, including HIV-1 and malnutrition [42].
The number of serotypes included in multivalent pneumococcal
vaccines is limited. Therefore, we explored an alternative strategy
to formulate a conjugate vaccine that took serotype-specific
mortality into account. Our results indicate that current strategies
for including serotypes in conjugate vaccines are appropriate for
children and for adults, if the vaccine contains at least ten
serotypes, in our study population. This is an interesting finding
because trials with pneumococcal conjugate formulations are
currently being conducted in adults and immunocompromised
patients (http://www.clinicaltrials.gov/).
Overall, the results of this study indicate that there has been a
decline in mortality after IPD during the last 30 y. This may be at
least partly explained by the introduction of more sensitive
diagnostic methods and improvements in therapy [48]. In spite of
these advancements, mortality following IPD in Denmark remains
remarkably high among adults, and changes in the trends in
mortality for particular groups of patients over time deserve to be
explored further in detail.
Our study has strengths and limitations. The large population
we studied was well-defined, and the follow-up was complete
because we used nationwide registries. Because there is universal
health coverage in Denmark, we probably identified nearly all IPD
episodes requiring hospitalization. We were able to adjust for a
wide range of potential confounders through access to indepen-
dent medical databases providing a complete medical history.
Misclassification of data on comorbidity and other confounders
might have led to some residual confounding, but we do not
expect misclassification to be differentially related to serotypes.
Moreover, we could not explore differences concerning other
pneumococcal virulence factors (e.g., pneumolysin, hyaluronidase,
catalase, and choline-binding protein A) or antibiotic resistance.
Such virulence factors may also play a role in IPD prognosis and
are a field for future research.
Our odds ratio estimates obtained by logistic regression
somewhat overestimated the true relative risk of mortality
associated with a given serotype if the mortality proportion was
high. We evaluated different regression models, and logistic
Figure 5. Multivariate logistic regression analysis of serotype-specific 30-d mortality associated with IPD in patients aged 5 y or
older with low comorbidity level (Charlson 0) (n=9,059). OR estimates controlled for age (in years), sex, IPD focus (meningitis or bacteremia),
time at diagnosis (in decades), alcoholism-related conditions. The reference group was patients with IPD caused by serotype 1 in each group. ORs
were calculated for serotypes with $50 IPD cases only.
doi:10.1371/journal.pmed.1000081.g005
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evaluate the association between pneumococcal serotypes and 30-
d mortality, since outcome was heterogeneous between serotypes
and fatal events were rare in subgroups of patients, particularly
among children. Even in this large study, it was not possible to
fully explore the association between serotypes and mortality in all
subgroups. For instance, we found that serotypes 3 and 19A were
associated with high-mortality OR estimates in older children and
adults compared to serotype 1, but we could not evaluate the
strength of these associations in children younger than 5 y because
of the low number of cases in this age group.
To our knowledge, this is the first and most comprehensive
population-based study to date that shows an important role of
individual pneumococcal capsular serotypes in the prognosis
associated with IPD.
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PCV Serotypes Ranked by Prevalence Ranked by Associated Crude Number of Deaths
Serotype
Cumulative
Cases
Cumulative
Deaths Serotype
Cumulative
Cases
Cumulative
Deaths Serotype
Cumulative
Cases
Cumulative
Deaths
14 292 2 14 292 2 6B 251 11
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There were no statistically significant differences (Chi-square test) between the cumulative number of deaths due to serotypes included in current PCV and the
cumulative number of deaths due to serotypes ranked according to prevalence and crude number of deaths, respectively.
doi:10.1371/journal.pmed.1000081.t002
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Background. Pneumococcal diseases—illnesses caused by
Streptococcus pneumoniae bacteria—are leading causes of
illness and death around the world. S. pneumoniae is
transmitted through contact with infected respiratory
secretions and usually causes noninvasive diseases such as
ear infections and bronchitis. Sometimes, however, the
bacteria invade the lungs (where they cause pneumonia),
the bloodstream (where they cause bacteremia), or the
covering of the brain (where they cause meningitis). These
invasive pneumococcal diseases (IPDs) are often fatal. One
million children die annually from pneumococcal disease,
many of them in developing countries. In the developed
world, however, IPDs mainly affect elderly people and
patients with chronic conditions such as diabetes and
alcoholism. Although pneumococcal diseases can
sometimes be treated successfully with antibiotics, many
patients die or develop long-term complications.
Consequently, vaccination with ‘‘pneumococcal
polysaccharide vaccine’’ (PPV) is recommended for
everyone over 65 years old and for people between 2 and
65 years old who are at high risk of developing IPD;
vaccination with ‘‘pneumococcal conjugate vaccine’’ (PCV)
is recommended for children younger than 2 years old who
are at high risk of IPDs.
Why Was This Study Done? S. pneumoniae is not a single
organism. There are actually more than 90 S. pneumoniae
variants or ‘‘serotypes.’’ These variants are coated with
different polysaccharides (complex sugar molecules) that are,
in part, responsible for the deleterious effects of S.
pneumonia infections. The same molecules also trigger the
human immune response that kills the bacteria.
Consequently, pneumococcal vaccines contain
polysaccharide mixtures isolated from the S. pneumoniae
serotypes responsible for most pneumococcal disease. But
are these serotypes also responsible for most of the deaths
caused by IPD? Until now, the few studies that have
investigated the association between S. pneumoniae
serotypes and death from IPD have yielded conflicting
results. Here, therefore, the researchers undertook a large
population-based study to discover whether there is an
association between specific pneumococcal serotypes and
death following IPD.
What Did the Researchers Do and Find? The researchers
linked data on the serotype of S. pneumoniae isolates sent to
the Danish National Neisseria and Streptococcus Reference
Center between 1977 and 2007 with clinical data from
national medical databases. After allowing for other factors
that might affect a person’s likelihood of dying from IPD (for
example, age and other illnesses), the researchers used
multivariate logistic regression analysis (a statistical
approach) to look for associations between S. pneumoniae
serotypes and death within 30 days of admission to hospital
for pneumococcal bacteremia or meningitis. Overall, 18% of
the nearly 19,000 people included in this analysis died within
30 days of hospital admission; among the children younger
than 5 years included in the study, the death rate was 3%.
Among patients 5 years old or older, nine S. pneumoniae
serotypes were associated with a more than 3-fold higher
death rate (mostly from bacteremia) than serotype 1, the
most common serotype isolated during the study.
Interestingly, in young children, a different set of serotypes
seemed to be associated with death. However, because so
few children died from IPD, this result is statistically
uncertain. The researchers’ results also show that age,
gender, having meningitis, having other illnesses, and
alcoholism all affected a patient’s chances of dying from IPD.
What Do These Findings Mean? These findings show
that specific pneumococcal serotypes strongly affect the
likelihood that a person aged 5 years or over will die within
30 days of admission to hospital with IPD. Importantly,
unlike previous studies, this study was large and
comprehensive—the Danish surveillance center covers
more than 90% of the Danish population—and the
researchers carefully took other factors into account that
might have affected a patient’s chances of dying from IPD.
Thus, these new insights into which pneumococcal serotypes
are most deadly could help in the design of new
pneumococcal vaccines, at least for people aged 5 years or
older. For younger children, however, the results are not as
informative and a similar study now needs to be done in
developing countries, where more young people die from
IPD.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000081.
N The US Centers for Disease Control and Prevention
provides information for patients and health professionals
on all aspects of pneumococcal disease and pneumococcal
vaccination
N The US National Foundation for Infectious Diseases has a
fact sheet on pneumococcal disease
N The UK Health Protection Agency also provides back-
ground information on pneumococcal disease
N The GAVI’s Pneumococcal Vaccines Accelerated Develop-
ment and Introduction Plan focuses on pneumococcal
vaccines for children
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